ParcelBio Unveils Programmable mRNA Platform Backed by $13M Financing
ParcelBio is using newly secured financing to advance its mRNA platform and its therapeutic pipeline including programs in autoimmune disease, oncology, and encoded protein therapeutics based on programmable RNA technology. The post ParcelBio Unveils Programmable mRNA Platform Backed by $13M Financing appeared first on GEN - Genetic Engineering and Biotechnology News.
Original Source
Read the full article at Genengnews →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.